

# Jennifer A. Brooks\*, MD, MPH, Adithya Srikanthan\*, BS, Amr H. Abdelhamid Ahmed, MBBCH, MMSc, Bo Wang, MD, PHD, Marika D. Russell, MD, Gregory W. Randolph, MD <sup>1</sup>Department of Otolaryngology, University of Rochester, <sup>2</sup>Department of Otolaryngology, Massachusetts Eye and Ear, <sup>3</sup>Fujian Medical University Union Hospital

## Introduction

- Recurrent laryngeal nerve (RLN) is a frequent site of extrathyroidal extension in advanced differentiated thyroid cancer.<sup>1,2</sup>
- Extrathyroidal extension into the RLN has been thought to have prognostic implications.<sup>3</sup>
- Compromising RLN integrity can lead to dysphonia, swallowing difficulty, and airway compromise.<sup>3</sup>
- The optimal surgical management of invaded RLNs requires investigation.

## Methods and Materials

- **Study Design:** Retrospective cohort study at a tertiary care academic center
- **Inclusion Criteria:** Patients who underwent surgery for differentiated thyroid carcinoma, with and without recurrent laryngeal nerve invasion from 1995-2015
- **Primary Outcome:** Survival outcomes at 5 and 10 years
- Statistical Analysis: t-tests, Mann-Whitney tests, chisquare, Fisher's Exact, Kaplan-Meier Survival analysis, and univariate/multivariate regression analysis


# Results

|                                       | No. (%)       |       |  |
|---------------------------------------|---------------|-------|--|
| Characteristics                       | Invaded group | Contr |  |
|                                       | N=59          | N     |  |
| RLN resected                          | 42/59 (71.2)  | 0/25  |  |
| Tumor Left on RLN                     | 15/59 (25.4)  | 0/25  |  |
| Pathologic Diagnosis                  |               |       |  |
| PTC                                   | 52/59 (88.1)  | 247/2 |  |
| FTC                                   | 7/59 (11.9)   | 1/25  |  |
| Lymph Nodes Positive for              | 4 (0, 10)     |       |  |
| Metastasis/Patient (N, median (IQR))* | 4 (0-10)      | 0     |  |
| Patients with Documented Nodal        | 20/E1 (01 0)  | 01/7  |  |
| Metastasis                            | 38/54 (81.8)  | 81/23 |  |

Table 1: Intraoperative findings in the Invaded and Control groups

Contact Gregory W. Randolph, MD FACS FACE FEBS (Endocrine) MAMSE Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 243 Charles Street, Boston, MA 02114 Email: <u>Gregory\_Randolph@meei.harvard.edu</u>; Phone: 617) 573-4115

# **Outcomes of Recurrent Laryngeal Nerve** Invasion in Differentiated Thyroid Carcinoma



## Figure 1: Survival outcomes between invade

### References

1. McCaffrey TV et al. Locally Invasive Papillary Thyroid Carcinoma: 1940-1990. Head & Neck 1994; 16: 165-172. Wu CW et al. International neuromonitoring study group guidelines 2018: Part II: Optimal recurrent laryngeal nerve management for invasive thyroid cancer-incorporation of surgical, laryngeal, and neural electrophysiologic data. Laryngoscope. 2018 Oct 6. doi: <u>10.1002/lary.27360</u>. <u>PMID: 30291765</u>.
 Shindo ML, Caruana SM, Kandil E, et al. Management of invasive well-differentiated thyroid cancer: an American Head and Neck Society consensus statement. Head Neck. 2014 Oct;36(10):1379-90. doi: 10.1002/hed.23619. Epub 2014 Aug 23. PMID: 24470171

4. Brooks JA, Abdelhamid Ahmed AH, Al-Qurayshi Z, et al. Recurrent Laryngeal Nerve Invasion by Thyroid Cancer: Laryngeal Function and Survival Outcomes. Laryngoscope. 2022 Nov;132(11):2285-2292. doi: 10.1002/lary.30115. Epub 2022 Apr 1. PMID: 35363394.

| ts  | Results  |  |                                |                   |  |
|---|--|--|--------------------------------|-------------------|--|
| Survival                                  |  | No. (%)  |                                |                   |  |
| - <del>-</del> - Invaded<br>Control       | Characteristics  | Invaded group                                    | Control group                  | Р                 |  |
|   | Postoperative Radiotherapy   | 18/57 (31.6)                                     | 4/246 (1.6)                    | <0.0001           |  |
|   | Postoperative Radioactive Iodine<br>(RAI)  | 42/57 (73.7)                                     | 140/248 (56.5)                 | 0.0164            |  |
|   | Postoperative RAI Dose, (mean ± SD)  | 157.8 ± 97.0                                     | 96.2 ± 39.7                    | <0.0001           |  |
|   | Postoperative Chemotherapy   | 11/57 (19.3)                                     | 3/248 (1.2)                    | <0.0001           |  |
|   | Locoregional Recurrence (LRR)  | 22/58 (37.9)                                     | 22/254 (8.7)                   | <0.0001           |  |
| 60 80                                     | Time to LRR (months, median & IQR)   | 13 (4.5-50)                                      | 23 (6.75-57.5)                 | 0.349             |  |
| vival                                     | Distant metastasis   | 16/65 (24.6)                                     | 3/250 (1.2)                    | <0.0001           |  |
| Invaded<br>Control                        | Table 2: Adjuvant Therapies received and Locoregional Recurrence throughout follow-up  |  |                                |                   |  |
|   | Discussion   |  |                                |                   |  |
|   |  | recurrence free survival and<br>0-year follow-up |                                |                   |  |
| 60 80<br>e Survival<br>Invaded<br>Control | <ul> <li>Invaded group had significantly higher rates of locoregional<br/>recurrence through through follow-up duration – reflection<br/>of aggressive disease state.</li> </ul> |  |                                |                   |  |
|   | <ul> <li>Invaded patients required adjuvant therapy at higher rates.</li> <li>Limitations: Single center study</li> </ul>  |  |                                |                   |  |
| <del> </del>                              | Linnations. Single Center Study  |  |                                |                   |  |
| 100 150                                   | Conclusions  |  |                                |                   |  |
| Irvival<br>Invaded<br>Control<br>         | <ul> <li>RLN invasion is associated including larger tumor siz</li> <li>RLN Invasion is associated</li> </ul>  | e and more r<br>d with a gene                    | nodal metasta<br>rally more ag | asis.<br>gressive |  |
| ded and control group patients            | nd survival ou   |  |                                |                   |  |

# MASSACHUSETTS EYE AND EAR